SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy
Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease
Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression
Abraxane and Gemcitabine Improves Overall Survival
Study Uncovers New Mechanism In Class of Chemotherapy Drugs
Adjuvant Radiation Treatment Shows Improved Survival In Elderly, Early-Stage Patients
Genetic Test Identifies Patients With High Risk of Mortality
Memantine Can Delay Onset Of Cognitive Function Decline
Doxepin Rinse Reduces Pain In Radiation Therapy Patients
Zaltrap Receives Positive Opinion For European Market From CHMP
NCI-Approved CTEP Trials For the Month of November
Trending Stories
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- An opportunity for Trump: Position U.S. cancer science to lead the world
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - In The Headlines: Wafik El-Deiry on how “America First” means investing in NCI
- Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges
